B. Malhotra

发表

Population Pharmacokinetics of Atorvastatin and Its Active Metabolites in Children and Adolescents With Heterozygous Familial Hypercholesterolemia: Selective Use of Informative Prior Distributions from Adults

M. Gastonguay, W. Knebel, B. Malhotra, 2013, Journal of clinical pharmacology.

Analytes of Interest and Choice of Dose: Two Important Considerations in the Design of Bioequivalence Studies with Atorvastatin

G. Kuan, R. Labadie, B. Malhotra, 2011 .

Population pharmacokinetics of the 5‐hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in western and east Asian populations

B. Malhotra, M. Oishi, Y. Tomono, 2014, Journal of clinical pharmacology.

Percutaneous Absorption and Pharmacokinetics of Eflornithine HC®l 13.9% Cream in Women with Unwanted Facial Hair

M. Palmisano, B Malhotra, R Noveck, 2001, Journal of clinical pharmacology.

Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole.

B. Malhotra, M. Oishi, K. Chiba, 2017, Drug metabolism and pharmacokinetics.

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

M. Dowty, B. Malhotra, Lisy Wang, 2021, Journal of clinical pharmacology.

Disposition and safety of omapatrilat in subjects with renal impairment

D. Sica, M. Jemal, T. Gehr, 2000, Clinical pharmacology and therapeutics.

Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial*

D. Webb, Hao Wang, B. Bart, 2007, Critical care medicine.

Effects of Hepatic Dysfunction on the Single‐Dose Pharmacokinetics of Fesoterodine

N. Wood, Z. Krastev, B. Malhotra, 2011, Journal of clinical pharmacology.

Modeling the route of administration-based enhancement in the brain delivery of EAB 515, studied by microdialysis.

R. Brundage, B. Malhotra, M. Lemaire, 1997, Journal of drug targeting.

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.

P. Glue, B. Malhotra, P. Crownover, 2011, British journal of clinical pharmacology.

Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics

B. Malhotra, M. Oishi, T. Suwa, 2010, Drug Metabolism and Disposition.

The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.

H. Simon, B. Malhotra, 2009, Swiss medical weekly.

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

L. Cardozo, D. Staskin, V. Khullar, 2010, BMC urology.

Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib

T. Nicholas, H. Valdez, L. Fostvedt, 2022, British journal of clinical pharmacology.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

B. Malhotra, K. Gandelman, C. Alvey, 2011, British journal of clinical pharmacology.

Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans.

K. Kripalani, Sanaullah Khan, B. Malhotra, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Oral Bioavailability and Disposition of [14C]Omapatrilat in Healthy Subjects

S. Kaul, B. Malhotra, R. Iyer, 2001, Journal of clinical pharmacology.

Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.

V. Roongta, K. Kripalani, B. Malhotra, 2001, Drug Metabolism And Disposition.

OMAPATRILAT , A SULFHYDRYL-CONTAINING VASOPEPTIDASE INHIBITOR IN HUMANS 1

V. Roongta, K. Kripalani, B. Malhotra, 2000 .

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.

M. Dickins, B. Malhotra, K. Gandelman, 2011, British journal of clinical pharmacology.

Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers

T. Nicholas, B. Malhotra, Pankaj Gupta, 2022, Clinical pharmacology in drug development.

Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents

Brahma N. Singh, B. Malhotra, 2004, Clinical pharmacokinetics.

Bmc Medical Research Methodology Open Access a Meta-analysis of the Placebo Response in Antimuscarinic Drug Trials for Overactive Bladder

P. Glue, M. Carlsson, B. Malhotra, 2022 .

A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

G. Kay, P. Bungay, M. Michel, 2011, British journal of clinical pharmacology.

The effects of reformulation: Improved therapeutic index

S. Macdiarmid, B. Malhotra, B. Sandage, 2008, Current Urology Reports.

Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder.

P. Reddy, T. Crook, B. Malhotra, 2012, Journal of pediatric urology.

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing

P. Glue, R. Labadie, S. Macdiarmid, 2010, European Journal of Clinical Pharmacology.

Relative Bioavailability of Chewable and Conventional Film-Coated TabletFormulations of Sildenafil 100 mg in Healthy Volunteers Under FastingConditions

B. Malhotra, P. Crownover, J. Ovalle, 2011 .

Relative Bioavailability Study of an Abuse-Deterrent Formulation ofExtended-Release Oxycodone with Sequestered Naltrexone (ALO-02)Versus Immediate-Release Oxycodone Tablets in Healthy Volunteers

Joanne Salageanu, Kyle T. Matschke, B. Malhotra, 2014 .

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

A. D. Rodrigues, M. Dowty, Cheng Chang, 2022, Clinical pharmacology and therapeutics.

Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.

Mohamed H. Shahin, T. Crook, T. Kitta, 2022, Journal of pediatric urology.

Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine

P. Maruff, G. Kay, B. Malhotra, 2012, Postgraduate medicine.

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

J. Silverberg, T. Bieber, A. Pink, 2021, The New England journal of medicine.

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

M. Dowty, M. O’Gorman, B. Malhotra, 2021, Journal of clinical pharmacology.

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.

J. Silverberg, T. Bieber, A. Pink, 2021, Immunotherapy.

Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study

L. Webster, Kyle T. Matschke, Almasa Bass, 2019, Therapeutic advances in drug safety.

Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users

L. Webster, Kyle T. Matschke, Almasa Bass, 2016, The American journal of drug and alcohol abuse.

Intranasal administration of crushed ALO‐02 (extended‐release oxycodone with sequestered naltrexone): A randomized, controlled abuse‐potential study in nondependent recreational opioid users

Kyle T. Matschke, Almasa Bass, B. Setnik, 2015, Journal of clinical pharmacology.

Single‐ and multiple‐dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended‐release oxycodone with sequestered naltrexone 40 mg twice daily to oxycontin 40 mg twice daily and extended‐release oxycodone with sequestered naltrexone 80 mg once d

Joanne Salageanu, Kyle T. Matschke, B. Malhotra, 2015 .

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO‐02, an extended release formulation of oxycodone with sequestered naltrexone

Joanne Salageanu, Kyle T. Matschke, B. Malhotra, 2015, Clinical pharmacology in drug development.

Single- and Multiple-Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Volunteers: A Comparison of Extended-Release Oxycodone With Sequestered Naltrexone 40mg Twice Daily to OxyContin 40mg Twice Daily and Extended-Release Oxycodone With Sequestered Naltrexone 80mg Once Dail

Joanne Salageanu, Kyle T. Matschke, B. Malhotra, 2015 .

Investigation of the Distribution of EAB 515 to Cortical ECF and CSF in Freely Moving Rats Utilizing Microdialysis

B. Malhotra, M. Lemaire, R. Sawchuk, 1994, Pharmaceutical Research.

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users

Kyle T. Matschke, Almasa Bass, B. Setnik, 2016, Pain medicine.

A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment

Almasa Bass, B. Setnik, G. Pixton, 2015, Pain.

High-performance liquid chromatographic analysis of (S)-α-amino-5-phosphonomethyl[1,1'-biphenyl]-3-propanoic acid (EAB 515) in brain and blood microdialysate (on-line) and in plasma ultrafiltrate of freely moving rats

B. Malhotra, M. Lemaire, R. Sawchuk, 1996 .

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug‐Drug Interaction for Fesoterodine When Coadministered With Mirabegron

T. Goosen, B. Malhotra, Jian Lin, 2019, Journal of clinical pharmacology.

The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.

N. Wood, B. Malhotra, K. Gandelman, 2009, Current medicinal chemistry.

Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.

N. Wood, B. Malhotra, R. Sachse, 2009, International journal of clinical pharmacology and therapeutics.

Thorough QT study of the effect of fesoterodine on cardiac repolarization.

N. Wood, B. Malhotra, K. Gandelman, 2010, International journal of clinical pharmacology and therapeutics.

Influence of food on the pharmacokinetic profile of fesoterodine.

N. Wood, B. Malhotra, R. Sachse, 2009, International journal of clinical pharmacology and therapeutics.

Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Fesoterodine

N. Wood, B. Malhotra, K. Gandelman, 2009, Journal of clinical pharmacology.

Pharmacokinetic profile of fesoterodine.

N. Wood, B Malhotra, B. Malhotra, 2008, International journal of clinical pharmacology and therapeutics.

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals

H. Valdez, M. Dowty, M. O’Gorman, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis

T. Nicholas, H. Valdez, L. Fostvedt, 2022, Clinical Pharmacokinetics.

P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development

J. Bauman, M. Dowty, T. Goosen, 2020 .

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

G. S. Walker, J. Bauman, J. Telliez, 2022, Drug Metabolism and Disposition.

15433 Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: Midazolam drug-drug interaction (DDI) study and oral contraceptive DDI study

G. Chan, M. Dowty, M. O’Gorman, 2020 .

Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)

Joanne Salageanu, Kyle T. Matschke, B. Malhotra, 2015, Clinical Drug Investigation.

Evaluation of drug–drug interactions with fesoterodine

N. Wood, B. Malhotra, Nolan Wood, 2009, European Journal of Clinical Pharmacology.

Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone.

I. Wilding, A. Connor, A. Thombre, 2015, Journal of controlled release : official journal of the Controlled Release Society.

The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.

A. D. de Kater, N. Friedmann, B. Malhotra, 2015, Journal of Opioid Management.